UroGen Pharma Ltd. (URGN): who owns it and who trades it
As of Nov 16, 2026, URGN insiders reported 15 open-market sales worth $4.8M and no purchases in the last 12 months, with 27% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark Schoenberg (Chief Medical Officer), with $4.5M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling UroGen Pharma
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns URGN
190 funds and institutions reported URGN shares worth $1.6B at the end of Q2 2026, about 91% of the company. The largest holder is Rtw Investments, LP with 9.3%.
Funds and institutions (13F) 91%Everyone else 9%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Rtw Investments, LP | 4.54M | 9.33% | $167M | No change |
| BlackRock, Inc. | 3.20M | 6.57% | $118M | +13% |
| Morgan Stanley | 2.58M | 5.29% | $94.8M | +1% |
| Kynam Capital Management, LP | 2.43M | 5.00% | $89.6M | +8% |
| Jefferies Financial Group Inc. | 2.20M | 4.51% | $80.9M | No change |
| SG Americas Securities, LLC | 2.05M | 4.21% | $75.5M | +24% |
| American Century Companies Inc | 1.69M | 3.46% | $62M | +3% |
| Acorn Capital Advisors, LLC | 1.67M | 3.43% | $61.6M | No change |
| California State Teachers Retirement System | 1.65M | 3.40% | $44.9M | +4169% |
| Point72 Asset Management, L.P. | 1.53M | 3.13% | $56.1M | – |
| Frontier Capital Management Co LLC | 1.51M | 3.10% | $55.5M | +15% |
| Opaleye Management Inc. | 1.44M | 2.96% | $53M | +1% |
| Silverarc Capital Management, LLC | 1.30M | 2.67% | $47.9M | -13% |
| Menora Mivtachim Holdings Ltd. | 1.15M | 2.37% | $42.4M | No change |
| D. E. Shaw & Co., Inc. | 1.15M | 2.35% | $42.2M | +12% |
| State Street Corp | 1.00M | 2.06% | $36.9M | +15% |
| Mpm Bioimpact LLC | 933,415 | 1.92% | $34.3M | -1% |
| Soleus Capital Management, L.P. | 829,810 | 1.70% | $30.5M | +14% |
| Goldman Sachs Group Inc | 819,834 | 1.68% | $30.2M | +37% |
| Migdal Insurance & Financial Holdings Ltd. | 770,909 | 1.58% | $28.4M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, URGN insiders reported $0 of open-market purchases and $4.8M of sales. 27% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | Chris Degnan | CFO | Sale | 2,202 | $36.69 | $80.8K | Form 4 |
| Sep 8, 2026 | Mark Schoenberg | Chief Medical Officer | Sale | 871 | $42.92 | $37.4K | Form 4 |
| Sep 8, 2026 | Jason Drew Smith | General Counsel | Sale | 1,519 | $42.54 | $64.6K | Form 4 |
| Aug 20, 2026 | Mark Schoenberg | Chief Medical Officer | Sale | 60,677 | $47.05 | $2.9M | Form 4 |
| Jul 9, 2026 | Mark Schoenberg | Chief Medical Officer | Sale plan | 10,000 | $40.00 | $400K | Form 4 |
| Jun 22, 2026 | Mark Schoenberg | Chief Medical Officer | Sale plan | 10,000 | $35.01 | $350K | Form 4 |
| Jun 8, 2026 | Mark Schoenberg | Chief Medical Officer | Sale | 5,222 | $27.30 | $143K | Form 4 |
| May 8, 2026 | Mark Schoenberg | Chief Medical Officer | Sale plan | 10,000 | $30.00 | $300K | Form 4 |
| Feb 3, 2026 | Jason Drew Smith | General Counsel | Sale | 3,217 | $19.69 | $63.3K | Form 4 |
| Feb 3, 2026 | Jason Drew Smith | General Counsel | Sale | 1,608 | $19.69 | $31.7K | Form 4 |
| Feb 3, 2026 | Jason Drew Smith | General Counsel | Sale | 2,654 | $19.69 | $52.3K | Form 4 |
| Feb 3, 2026 | Mark Schoenberg | Chief Medical Officer | Sale | 1,843 | $19.69 | $36.3K | Form 4 |
| Feb 3, 2026 | Mark Schoenberg | Chief Medical Officer | Sale | 3,686 | $19.69 | $72.6K | Form 4 |
| Feb 3, 2026 | Mark Schoenberg | Chief Medical Officer | Sale | 1,844 | $19.69 | $36.3K | Form 4 |
| Nov 19, 2025 | Mark Schoenberg | Chief Medical Officer | Sale plan | 10,000 | $25.00 | $250K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark Schoenberg | Chief Medical Officer | – | $4.5M | Sep 8, 2026 |
| Jason Drew Smith | General Counsel | – | $212K | Sep 8, 2026 |
| Chris Degnan | Chief Financial Officer | – | $80.8K | Oct 8, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
URGN short interest
High short interest. 10.4% of URGN shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 24%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.11M URGN shares were sold short, 10.4% of the shares outstanding, down 8.9% from the report before. At the average daily volume of 1.00M shares, buying them all back would take about 5.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.11M | 10.41% | -9% | 1.00M | 5.1 |
| Oct 15, 2026 | 5.61M | 11.47% | -28% | 1.14M | 4.9 |
| Sep 30, 2026 | 7.77M | 15.89% | +24% | 783,547 | 9.9 |
| Sep 15, 2026 | 6.25M | 12.78% | No change | 681,702 | 9.2 |
| Aug 31, 2026 | 6.25M | 12.78% | +22% | 919,418 | 6.8 |
| Aug 14, 2026 | 5.12M | 10.48% | +12% | 1.07M | 4.8 |
| Jul 31, 2026 | 4.59M | 9.39% | -19% | 691,634 | 6.6 |
| Jul 15, 2026 | 5.69M | 11.68% | -9% | 825,084 | 6.9 |
| Jun 30, 2026 | 6.22M | 12.76% | -5% | 660,094 | 9.4 |
| Jun 15, 2026 | 6.56M | 13.46% | -5% | 664,053 | 9.9 |
| May 29, 2026 | 6.92M | 14.21% | +2% | 623,859 | 11.1 |
| May 15, 2026 | 6.76M | 13.88% | -7% | 1.16M | 5.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
UroGen Pharma company events
UroGen Pharma filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 20, 2026AnnouncementUroGen Pharma Ltd., through its wholly owned subsidiary UroGen Pharma, Inc., entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd., a company organized under the laws of Israel. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 23, 2026LeadershipAt the Annual Meeting, the Company’s shareholders also approved (i) an amendment to the Company’s Amended and Restated Non-Employee Director and Officer Compensation Policy in relation to directors’ and officers’ insurance and (ii) an amendment to the Company’s 2017 Equity Incentive Plan (the “2017… Filing
- Jun 2, 2026AnnouncementUroGen Pharma Ltd. and UroGen Pharma Inc. (collectively, “the Company”) issued a press release announcing that the Company entered into a settlement and license agreement with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. (collectively, “Teva”) that resolves the patent litigation… Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 2, 2026ResultsReleased financial results. Filing
- Mar 2, 2026AgreementUroGen Pharma Ltd., and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
UroGen Pharma financials
Famous investors that hold URGN
4 of the 50 well-known investors we track reported holding URGN in their latest 13F filing. The largest position is Israel Englander's, worth $10.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 268,902 | $10.9M | 0.0% | +152% |
| Cathie Wood · ARK Investment Management | Q3 2026 | 54,250 | $2.2M | 0.0% | -47% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 35,665 | $1.4M | 0.0% | +175% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 14,900 | $605K | 0.0% | -79% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named URGN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | The Toronto-Dominion Bank | 13G/A | 5.7% |
| Nov 13, 2026 | The Toronto-Dominion Bank | 13G/A | 5.7% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 6.3% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 6.3% |
Questions about UroGen Pharma Ltd. (URGN) stock
Who owns the most URGN stock?
The largest reported owner of UroGen Pharma Ltd. (URGN) is Rtw Investments, LP, with 9.3% of the company. In total, 190 funds and institutions reported holding URGN at the end of Q2 2026, together about 91% of the shares. See the largest owners.
Are URGN insiders buying or selling?
In the last 12 months, URGN insiders reported no open-market purchases and 15 sales worth $4.8M. The latest trade was on Oct 8, 2026. See every trade.
What is the short interest in URGN?
As of Oct 30, 2026, 5.11M URGN shares were sold short, 10.4% of the shares outstanding, down 8.9% from the report before. At the average daily volume of 1.00M shares, buying them all back would take about 5.1 trading days (days to cover). See the history.
Which famous investors hold URGN?
4 of the 50 well-known investors we track reported URGN in their latest 13F filing, including Israel Englander, Cathie Wood, Ken Griffin. The largest position is worth $10.9M. See all holders.
Executive pay
UroGen Pharma's chief executive was paid a total of $4.3M for the year ended Dec 31, 2025, up 4% from $4.1M the year before. In the last 12 months, UroGen Pharma's executives and directors bought no stock on the open market and sold $4.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.